Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Sell
38
MGNX Quote, Financials, Valuation and Earnings
Last price:
$1.40
Seasonality move
:
7.11%
Day range:
$1.38 - $1.45
52-week range:
$0.99 - $3.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.69x
P/B ratio:
1.32x
Volume:
662.5K
Avg. volume:
1.2M
1-year change:
-58.82%
Market cap:
$88.6M
Revenue:
$150M
EPS (TTM):
-$1.21
Analysts' Opinion
-
Consensus RatingMacroGenics, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $3.40, MacroGenics, Inc. has an estimated upside of 142.86% from its current price of $1.40.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $1.40.
Fair Value
-
According to the consensus of 6 analysts, MacroGenics, Inc. has 142.86% upside to fair value with a price target of $3.40 per share.
MGNX vs. S&P 500
-
Over the past 5 trading days, MacroGenics, Inc. has overperformed the S&P 500 by 2.83% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
MacroGenics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
MacroGenics, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter MacroGenics, Inc. reported revenues of $72.8M.
Earnings Growth
-
MacroGenics, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter MacroGenics, Inc. reported earnings per share of $0.27.
Enterprise value:
49.4M
EV / Invested capital:
0.28x
Price / LTM sales:
0.69x
EV / EBIT:
--
EV / Revenue:
0.39x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-0.30x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$88.7M
Return On Assets:
-29.74%
Net Income Margin (TTM):
-59.46%
Return On Equity:
-88.47%
Return On Invested Capital:
-50.41%
Operating Margin:
25.59%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $121.1M | $141.3M | $127.6M | $110.7M | $72.8M | |
| Gross Profit | $100.3M | $127M | $88.7M | $107M | $59.5M | |
| Operating Income | -$106.9M | -$107.1M | -$113.6M | $54.2M | $18.6M | |
| EBITDA | -$95.9M | -$99.7M | -$106.1M | $56M | $20.4M | |
| Diluted EPS | $0.80 | -$1.57 | -$1.21 | $0.90 | $0.27 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $334.7M | $147.8M | $291.3M | $222.2M | $232.1M | |
| Total Assets | $392.2M | $195.3M | $340M | $264.5M | $270.8M | |
| Current Liabilities | $68.9M | $50M | $51.3M | $59.3M | $44.5M | |
| Total Liabilities | $100.7M | $72.4M | $146M | $144.4M | $203.8M | |
| Total Equity | $291.4M | $123M | $194M | $120.1M | $67M | |
| Total Debt | $26.5M | $17M | $30.2M | $29.4M | $102.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$20.8M | -$58M | -$162.5M | $60.2M | -$30.2M | |
| Cash From Investing | -$124.7M | $146.7M | -$6.6M | $35.6M | -$20.4M | |
| Cash From Financing | $151.4M | $1.1M | $69.6M | -$68K | -- | |
| Free Cash Flow | -$22.4M | -$61.7M | -$164.8M | $59.6M | -$30.6M | |
MGNX
Sector
Market Cap
$88.6M
$28.6M
Price % of 52-Week High
38.89%
51.66%
Dividend Yield
0%
0%
Shareholder Yield
-13.99%
-1.34%
1-Year Price Total Return
-58.82%
-20.19%
Beta (5-Year)
1.516
0.519
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.39
200-day SMA
Sell
Level
$1.60
Bollinger Bands (100)
Sell
Level
1.45 - 1.77
Chaikin Money Flow
Sell
Level
-10.4M
20-day SMA
Sell
Level
$1.43
Relative Strength Index (RSI14)
Sell
Level
44.51
ADX Line
Sell
Level
9.85
Williams %R
Neutral
Level
-65.2174
50-day SMA
Sell
Level
$1.57
MACD (12, 26)
Sell
Level
-0.02
25-day Aroon Oscillator
Buy
Level
16
On Balance Volume
Sell
Level
-7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-5.336)
Sell
CA Score
(Annual)
Level (-2.1474)
Sell
Beneish M-Score
(Annual)
Level (-1.8132)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (1.5783)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
Stock Forecast FAQ
In the current month, MGNX has received 1 Buy ratings 5 Hold ratings, and 0 Sell ratings. The MGNX average analyst price target in the past 3 months is $3.40.
-
Where Will MacroGenics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that MacroGenics, Inc. share price will rise to $3.40 per share over the next 12 months.
-
What Do Analysts Say About MacroGenics, Inc.?
Analysts are divided on their view about MacroGenics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that MacroGenics, Inc. is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is MacroGenics, Inc.'s Price Target?
The price target for MacroGenics, Inc. over the next 1-year time period is forecast to be $3.40 according to 6 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is MGNX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for MacroGenics, Inc. is a Hold. 5 of 6 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of MGNX?
You can purchase shares of MacroGenics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase MacroGenics, Inc. shares.
-
What Is The MacroGenics, Inc. Share Price Today?
MacroGenics, Inc. was last trading at $1.40 per share. This represents the most recent stock quote for MacroGenics, Inc.. Yesterday, MacroGenics, Inc. closed at $1.40 per share.
-
How To Buy MacroGenics, Inc. Stock Online?
In order to purchase MacroGenics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get MGNX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MGNX
Sector
P/E ratio
--
24.09x
PEG ratio
-0.01x
-0.01x
P/B ratio
1.32x
1.84x
Price / LTM sales
0.69x
1.60x
Growth Metrics
MGNX
Sector
Revenue growth
-34.21%
4.73%
Earnings growth
-70.38%
11.06%
Revenue (5-year growth)
18.5%
6.5%
Earnings forecast
-$0.51
-$0.20
Profitability
MGNX
Sector
Profitability FY 2024
$130.1M
$3.6M
Return on invested capital
-50.41%
-31.16%
Return on assets
-29.74%
-27.72%
Return on equity
-88.47%
-36.97%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
19
Estimated Next Earnings Date
Feb
11
Balance Sheet
MGNX
Sector
Total cash
$146.4M
$27M
Short term investments
$18.8M
$26M
Total assets
$270.6M
$79.7M
Long term debt
$102.1M
$3.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
73
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 39x
Alerts
Buy
80
FEIM alert for Dec 13
Frequency Electronics, Inc. [FEIM] is up 28.76% over the past day.
Buy
57
MOD alert for Dec 13
Modine Manufacturing Co. [MOD] is down 15.32% over the past day.
Sell
42
OKLO alert for Dec 13
Oklo, Inc. [OKLO] is down 14.91% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
